[
  {
    "ts": null,
    "headline": "Bristol Myers says FDA updates Camzyos label to simplify treatment",
    "summary": "Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and expanding patient eligibility by reducing contraindications. “In addition to the established efficacy of Camzyos, these meaningful updates to the label reinforce the strong safety profile of the therapy. With robust clin",
    "url": "https://finnhub.io/api/news?id=685b51e9f6bce0a47f149a28ce78b5f07327b2b5e4461d8aee266669f52ebde8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745060409,
      "headline": "Bristol Myers says FDA updates Camzyos label to simplify treatment",
      "id": 134018074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and expanding patient eligibility by reducing contraindications. “In addition to the established efficacy of Camzyos, these meaningful updates to the label reinforce the strong safety profile of the therapy. With robust clin",
      "url": "https://finnhub.io/api/news?id=685b51e9f6bce0a47f149a28ce78b5f07327b2b5e4461d8aee266669f52ebde8"
    }
  }
]